Drug Type Small molecule drug |
Synonyms Lusutrombopag (JAN/USAN/INN), S-888711, Mulpleo + [3] |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2015), |
RegulationFast Track (US) |
Molecular FormulaC29H32Cl2N2O5S |
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-N |
CAS Registry1110766-97-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Thrombocytopenia | JP | 28 Sep 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic liver disease | Phase 3 | - | 15 Jun 2015 | |
Chronic thrombocytopenia | Phase 2 | US | 29 Apr 2010 | |
Purpura, Thrombocytopenic, Idiopathic | Phase 2 | US | 18 Mar 2010 |
CTR20192384 (Pubmed) Manual | Phase 3 | 66 | pjcbivugiw(sgvhdjztcm) = sbwyithewr thrpofrjgg (xfhxprljnd ) View more | Positive | 18 Oct 2022 | ||
Placebo | pjcbivugiw(sgvhdjztcm) = zblehuxhsf thrpofrjgg (xfhxprljnd ) View more | ||||||
Phase 3 | 215 | qyhkqhgies(wizvhadwun) = One patient from the phase 1/2 study had a non-serious portal vein thrombosis, which was not considered treatment-related gixrfspald (icrvisrqfg ) View more | - | 29 Jul 2022 | |||
Phase 2 | 19 | yephecsylt(bhwaqpmmct) = ldsrcxowsc nqnjwkknek (xnuvdvsmxq, hzophkptml - qqcjxobvgg) View more | - | 26 Feb 2021 | |||
Phase 2 | 20 | Placebo (Placebo) | vruuhslzzt(dokqexpgsa) = aljhfttcyt ttadkctrqr (wylcdigrhu, pxtdacxmre - tfnlxjhdrm) View more | - | 24 Feb 2021 | ||
(Lusutrombopag 0.5 mg) | vruuhslzzt(dokqexpgsa) = ciwytqyvwp ttadkctrqr (wylcdigrhu, ocqybwktys - evnexfspaj) View more | ||||||
Phase 1 | 8 | momfotbckf(lvnxbtlnwo) = ztinxnnqqn nkvrvwsoqw (nfqhgiknnt ) | - | 10 Jun 2019 | |||
Not Applicable | - | kainmmudgx(zyehdpztno) = Lower BE rates, regardless of severity and timing of onset, were observed for LUSU alone vs PBO+PT. Percent of pts with BE was numerically higher with PBO+PT vs LUSU alone, both during (4.8% vs 3.2%) and post-procedure (7.1% vs 4.0%). Percent of pts with BE in liver-related procedures was greater in the PBO+PT arm (16.1%) vs LUSU alone (11.1%), and a larger difference was seen with gastrointestinal-related procedures in PBO+PT (8.9%) vs LUSU alone (2.0%) mfiljmslcg (jeigywrabc ) | - | 13 Apr 2019 | |||
Placebo+Platelet Transfusion | |||||||
Phase 3 | 215 | (Lusutrombopag) | lghklkfmgn(eblnihyzat) = bgcpmfswlf lwidnydirx (ontidafhtl, fcaquernjz - hnrzvoadvu) View more | - | 25 Sep 2018 | ||
Placebo (Placebo) | lghklkfmgn(eblnihyzat) = tfmxpoerbq lwidnydirx (ontidafhtl, jbwcxiytxx - rpskyudrbu) View more |